Robert W. Malone

Before I could even get one cup of coffee down the hatch this morning, I was hit with a barrage of emails, texts, and phone calls asking me for quotes concerning the press release issued by Moderna regarding their decision to sue BioNTech/Pfizer for patent infringement relating to the insanely profitable SARS-CoV-2 mRNA “vaccine” products marketed by BioNTech/Pfizer (“Comirnaty” – licensed but not actually marketed in the USA).

… Let’s take a moment to provide some key details relating to patent law, as there are a few things that one must understand to interpret the new claims being made by Moderna against BioNTech.

… To provide additional context, there is apparently another lawsuit between NIH/NIAID/Vaccine Research Center and Moderna over who owns the rights to the specific vaccine which Moderna has sold to the US Government and throughout the world.

… There is also a lawsuit battle ongoing between the cationic lipid formulation companies which were spun out of the University of British Columbia – Arbutus and Alnylam, which some in Canada believe are owned to a significant extent by the family of Justin Trudeau.

… Moderna is asserting that it has patent rights relating to both broad fundamental composition of the mRNA as a (modified) chemical structure, and to the use of any full length coronavirus spike protein in a lipid nanoparticle formulation for a coronavirus (vaccine).